Sugi Predict

Sugi Predict / Compounds / SCHEMBL6789755

SCHEMBL6789755

SCHEMBL6789755

NC(=O)c1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)cn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 8/20 0.45
▸ UMPS P11172 1/20 0.45
▸ LMNA P02545 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ GLA P06280 1/20 0.42
▸ EIF4E P06730 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ TOP1 P11387 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ THPO P40225 1/20 0.42
▸ PMP22 Q01453 1/20 0.42
▸ PYGL P06737 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ BLM P54132 1/20 0.41
▸ TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6797099 1.00 SLC5A2 (0.45) SLC5A2UMPSLMNASMN1; SMN2ALDH1A1
SCHEMBL6791968 0.83 SLC5A2 (0.57) SLC5A2
SCHEMBL6797029 0.83 SLC5A2 (0.57) SLC5A2
SCHEMBL5486410 0.80 SLC5A2 (0.47) SLC5A2PYGL
SCHEMBL5483976 0.80 SLC5A2 (0.47) SLC5A2PYGL
SCHEMBL6789901 0.80 SLC5A2 (0.48) SLC5A2UMPSLMNASMN1; SMN2ALDH1A1
SCHEMBL6789910 0.80 SLC5A2 (0.48) SLC5A2UMPSLMNASMN1; SMN2ALDH1A1
Bromide SCHEMBL8817735 0.79 SLC5A2 (0.46) SLC5A2PYGL
SCHEMBL5482570 0.79 SLC5A2 (0.48) SLC5A2PYGL
SCHEMBL6934058 0.79 SLC5A2 (0.48) SLC5A2PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230116276-A1 DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS COE WILLIAM B (US) 2023-04-13 — — US claimed
US-11612616-B2 Aldehyde functional monoterpenoids for the treatment of coronavirus infection COE WILLIAM B (US) 2023-03-28 — — US claimed
WO-2021188575-A1 DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS COE WILLIAM B (US) 2021-09-23 — — WO claimed
US-20210283162-A1 ALDEHYDE FUNCTIONAL MONOTERPENOIDS FOR THE TREATMENT OF CORONAVIRUS INFECTION COE WILLIAM B (US) 2021-09-16 — — US claimed
US-10993958-B1 Aldehyde functional monoterpenoids for the treatment of coronavirus infection COE WILLIAM B (US) 2021-05-04 — — US claimed
US-20230116276-A1 DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS COE WILLIAM B (US) 2023-04-13 — — US disclosed
US-20230116276-A1 DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS COE WILLIAM B (US) 2023-04-13 — — US disclosed
US-11612616-B2 Aldehyde functional monoterpenoids for the treatment of coronavirus infection COE WILLIAM B (US) 2023-03-28 — — US disclosed
US-11612616-B2 Aldehyde functional monoterpenoids for the treatment of coronavirus infection COE WILLIAM B (US) 2023-03-28 — — US disclosed
WO-2021188575-A1 DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS COE WILLIAM B (US) 2021-09-23 — — WO disclosed
WO-2021188575-A1 DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS COE WILLIAM B (US) 2021-09-23 — — WO disclosed
US-20210283162-A1 ALDEHYDE FUNCTIONAL MONOTERPENOIDS FOR THE TREATMENT OF CORONAVIRUS INFECTION COE WILLIAM B (US) 2021-09-16 — — US disclosed
US-20210283162-A1 ALDEHYDE FUNCTIONAL MONOTERPENOIDS FOR THE TREATMENT OF CORONAVIRUS INFECTION COE WILLIAM B (US) 2021-09-16 — — US disclosed
US-10993958-B1 Aldehyde functional monoterpenoids for the treatment of coronavirus infection COE WILLIAM B (US) 2021-05-04 — — US disclosed
US-10993958-B1 Aldehyde functional monoterpenoids for the treatment of coronavirus infection COE WILLIAM B (US) 2021-05-04 — — US disclosed
US-20040266723-A1 Antiviral agents for treatment of Flaviviridae infections PHARMASSET, INC. 2004-12-30 — — US disclosed
CN-1527836-A Antiviral agents for treatment of flaviviridae infections — 2004-09-08 — — CN disclosed
EP-1366055-A2 ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS Pharmasset Limited (BB) 2003-12-03 — — EP disclosed
WO-2002048165-A2 ANTIVIRAL AGENTS FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS PHARMASSET LTD. (BB) 2002-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210283162-A1 ALDEHYDE FUNCTIONAL MONOTERPENOIDS FOR THE TREATMENT OF CORONAVIRUS INFECTION ACE2, ZC3HAV1, ACE SLC5A2 2266/4885UMPS 54/4885LMNA 3783/4885
US-10993958-B1 Aldehyde functional monoterpenoids for the treatment of coronavirus infection ACE2, ZC3HAV1, ACE SLC5A2 2266/4885UMPS 54/4885LMNA 3783/4885
US-20230116276-A1 DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS ACE2, ACE, ALDH2 SLC5A2 580/4885UMPS 468/4885LMNA 4102/4885
US-11612616-B2 Aldehyde functional monoterpenoids for the treatment of coronavirus infection ACE2, ZC3HAV1, ACE SLC5A2 2266/4885UMPS 54/4885LMNA 3783/4885
US-20040266723-A1 Antiviral agents for treatment of Flaviviridae infections HAVCR2, MAVS, EIF2AK2 SLC5A2 309/4885UMPS 454/4885LMNA 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.